Ibudilast is under clinical development by MediciNova and currently in Phase II for Chemotherapy Induced Peripheral Neuropathy. According to GlobalData, Phase II drugs for Chemotherapy Induced Peripheral Neuropathy does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Ibudilast LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ibudilast overview
Ibudilast (Ketas) is an anti-inflammatory and neuroprotective agent. It is formulated in the form of hard gelatin capsules for oral route and intravenous route of administration. Ketas capsule is indicated for the treatment of asthma and improvement of dizziness due to chronic cerebral circulatory disorders associated with cerebral infarction.
Ibudilast is under development for the treatment of amyotrophic lateral sclerosis (ALS), primary and secondary progressive multiple sclerosis, alcohol dependence, opium withdrawal syndrome, methamphetamine addiction (drug addiction), degenerative cervical myelopathy, chemotherapy-induced peripheral neuropathy, chlorine-induced acute lung injury and acute respiratory distress syndrome in patients infected by the COVID-19 coronavirus, glaucoma, Pneumonia, retinal damage and metastatic uveal melanoma. It is administered through oral route in the form of capsules.
It was also under development for chronic medication overuse headache, cerebrovascular disorders, globoid cell leukodystrophy (Krabbe Disease), neuropathic pain and post traumatic brain injury.
MediciNova overview
MediciNova is a biopharmaceutical company. It develops novel therapeutics for serious diseases with unmet medical needs. The company’s product pipeline includes MN-166 (ibudilast), MN-001 (tipelukast) and MN-029 (denibulin), targeting a range of neurological, fibrotic, respiratory, and oncological disorders. MediciNova‘s leading candidate, MN-166 (ibudilast), is under development for progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and acute respiratory distress syndrome (ARDS). MN-001 (tipelukast) is being developed for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MN-029 (denibulin) is focused on solid tumor cancers. MediciNova is headquartered in La Jolla, California, the US.
For a complete picture of Ibudilast’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
